Market Place
Sourcing Support
Bayer submits EU marketing application for menopause relief drug
15 Oct 2024 //
REUTERS
FDA Accepts New Drug Application For Elinzanetant
09 Oct 2024 //
BUSINESSWIRE
Bayer to Unveil New Data From Phase III OASIS 3 Study on Elinzanetant
05 Sep 2024 //
BUSINESSWIRE
JAMA Publishes Elinzanetant Phase III Data
23 Aug 2024 //
BUSINESSWIRE
Elinzanetant reduces frequency & severity of hot flashes associated menopause
17 May 2024 //
INDINPHARMAPOST
Elinzanetant Significantly Reduces Menopausal Hot Flashes
16 May 2024 //
BUSINESSWIRE
Bayer: Late-Breaking Data Unveiling for Elinzanetant in Menopause
08 May 2024 //
BUSINESSWIRE
Bayer to seek approval for menopausal relief drug after third trial win
20 Mar 2024 //
REUTERS
Positive topline results from Phase III long-term study OASIS 3 support
19 Mar 2024 //
BUSINESSWIRE
Bayer’s $425M non-hormonal therapy for menopause symptoms clears first PhIII test
09 Jan 2024 //
ENDPTS
Bayer’s elinzanetant meets key secondary endpoints in Phase III studies
08 Jan 2024 //
BUSINESSWIRE
Bayer starts Phase II study NIRVANA to evaluate elinzanetant
08 Jan 2024 //
BUSINESSWIRE
Phase IIb Study of Investigational Compound Elinzanetant Evaluated Efficacy in Postmenopausal Patients
02 Feb 2023 //
BUSINESSWIRE
Bayer Extends Program for Investigational Product Elinzanetant With PIII Study
07 Nov 2022 //
BUSINESSWIRE
Bayer extends elinzanetant trials to include breast cancer
17 Oct 2022 //
PHARMAPHORUM
Bayer Starts Phase III Clinical Development Program OASIS With Elinzanetant
31 Aug 2021 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.